Long-term safety study of buntanetap for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests the long-term safety of an investigational drug called buntanetap for people with Alzheimer's disease. It is open to those who have already taken buntanetap in a previous trial and aims to see how safe it is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous Alzheimer's trial with buntanetap.
- You need a study partner who spends at least 10 hours per week with you and can come to study visits.
- You must be able to give informed consent, or have a legal representative if your memory is very impaired.
- You must be in generally good health, with no unstable medical conditions.
- You must not have certain other types of dementia, uncontrolled diabetes, heart rhythm problems, or recent suicidal thoughts.
- You must not be pregnant or breastfeeding, and must agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Hear when a new Alzheimer's Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.